Rachael L. Morton

Last updated

Rachael L. Morton is an Australian academic, Professor and Principal Research Fellow of Health Economics in the Faculty of Medicine and Health, University of Sydney. [1]

Contents

Morton is an international leader in the economic evaluation of chronic kidney disease and melanoma skin cancer.[ citation needed ]

Education and Career

Morton graduated with a PhD from the University of Sydney in 2011. [2]

Morton is currently Director of Health Economics & Health Technology Assessment and deputy director of the NHMRC Clinical Trials Centre. [1]

Board Director, Australian Clinical Trials Alliance [3] (ACTA) 2018–2024; Past President, Heath Services Research Association Australia and New Zealand [4] (HSRAANZ); Program Chair - International Health Economics Association [5] (IHEA); Health Economists Study Group UK [6] (HESG). [1]

Health Economics Research

Morton is an international leader in the economic evaluation of chronic kidney disease and melanoma prevention, diagnosis, and treatment.[ citation needed ]

Morton's research has had a major influence on funding policy (US Medicare & Medicaid) for dialysis payments and chronic kidney disease; [7] [ failed verification ] Australian Medicare providing economic evidence for new MBS items. [8] Her research has changed international clinical practice guidelines in melanoma (UK, US, Germany, Brazil, Australia [9] ) kidney disease (Kidney Disease Improving Global Outcomes [KDIGO] guidelines, [10] CARI [Australia]), for transplantation and end-of-life care; and infectious diseases through the European Centre for Disease Control [EU].

Awards and Recognition

In 2013 Morton won an NHMRC Sidney Sax Fellowship to Oxford University.[ citation needed ]

In 2019 CI Morton won the Distinguished Investigator award for Health Services Research. [11]

In 2024, Morton won the ACTA Trial of the Year, Health Economics Alongside Trials (HEAT) Excellence award for her high impact cost-effectiveness analysis of a melanoma prevention strategy using personalised genomics. [12] [13]

Additionally in 2024, Morton was a winner in the Eureka Science Prize – Aspire Scholarship Excellence in Interdisciplinary Scientific Research, for the ACRF Australian Centre for Excellence in Melanoma Imaging and Diagnosis. [14]

Top Publications

Source: [15]

1.   The views of patients and carers in treatment decision making for chronic kidney disease: a systematic review and thematic synthesis of qualitative studies. BMJ. [16]

2.   Chronic Kidney Disease. The Lancet. [17]

3.   Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. Journal of Clinical Oncology. [18]

4.   The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Euro Surveillance. [19]

5.   Impact of CKD on Household Income. Kidney International Reports. [20]

6.   Incorporating carbon into health care: adding carbon emissions to health technology assessments. The Lancet Planetary Health. [21]

7.   The Symptom Monitoring with Feedback Trial (SWIFT): Protocol for a registry-based cluster randomised controlled trial in haemodialysis. Trials. [22]

8.   Patient- reported outcome measures (PROMs) to guide clinical care: recommendations and challenges. MJA. [23]

9.    Kidney health in the context of economic development. Nature Reviews, Nephrology. [24]

10.  Expedited transfer from scene for refractory out-of-hospital cardiac arrest: an Australian prospective, multicentre, parallel, open-label randomised clinical trial. Accepted The Lancet Respiratory Medicine. (May, 2025)

References

  1. 1 2 3 Morton, Rachael (2025-07-21). "People". Th University of Sydney.
  2. ↑ Morton, Rachael (2025-07-21). "Profile/rachaelmorton". Linked In.
  3. ↑ "ACTA – Australian Clinical Trials Alliance – Better health through best evidence". clinicaltrialsalliance.org.au/.
  4. ↑ "HSRAANZ - Using research to improve health services & systems". HSRAANZ.
  5. ↑ "Home". IHEA.
  6. ↑ "Health Economists' Study Group – The UK Health Economics Association". March 1, 2019.
  7. ↑ "Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, Conditions for Coverage for End-Stage Renal Disease Facilities, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model". Federal Register. 2024-11-12. Retrieved 2025-07-22.
  8. ↑ chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.msac.gov.au/sites/default/files/documents/1485.1%2520Final%2520PSD_Apr2020.pdf
  9. ↑ chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.cancer.org.au/assets/pdf/archived-diagnosis-and-management-of-melanoma-guidelines-11-june-2018
  10. ↑ Davison, Sara N.; Levin, Adeera; Moss, Alvin H.; Jha, Vivekanand; Brown, Edwina A.; Brennan, Frank; Murtagh, Fliss E. M.; Naicker, Saraladevi; Germain, Michael J.; O'Donoghue, Donal J.; Morton, Rachael L.; Obrador, Gregorio T. (2015-09-01). "Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care". Kidney International. 88 (3): 447–459. doi: 10.1038/ki.2015.110 . ISSN   0085-2538. PMID   25923985.
  11. ↑ Green, Sarah (2019-12-12). "A/Professor Rachael Morton - Distinguished Investigator (Mid-Career)". HSRAANZ. Retrieved 2025-07-22.
  12. ↑ "NHMRC Clinical Trial Centre | Improving Health Outcomes". ctc.usyd.edu.au. Retrieved 2025-07-21.
  13. ↑ "Australian Clinical Trials shine at annual ACTA Awards – ACTA – Australian Clinical Trials Alliance". clinicaltrialsalliance.org.au/. 2024-05-20. Retrieved 2025-07-21.
  14. ↑ News, Opening Hours Open Daily 10am-5pmClosed Christmas DayFree General Entry Address 1 William StreetSydney NSW 2010 Australia Phone +61 2 9320 6000 www australian museum Copyright © 2025 The Australian Museum ABN 85 407 224 698 View Museum. "2024 Australian Museum Eureka Prizes finalists". The Australian Museum. Retrieved 2025-07-21.{{cite web}}: |last= has generic name (help)CS1 maint: numeric names: authors list (link)
  15. ↑ "Rachael Morton". scholar.google.com.au. Retrieved 2025-07-21.
  16. ↑ Morton, R. L.; Tong, A.; Howard, K.; Snelling, P.; Webster, A. C. (2010-01-19). "The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies". BMJ. 340: c112. doi:10.1136/bmj.c112. ISSN   0959-8138. PMC   2808468 . PMID   20085970.
  17. ↑ Webster, Angela C.; Nagler, Evi V.; Morton, Rachael L.; Masson, Philip (2017-03-25). "Chronic Kidney Disease" . The Lancet. 389 (10075): 1238–1252. doi:10.1016/S0140-6736(16)32064-5. ISSN   0140-6736. PMID   27887750.
  18. ↑ Watts, Caroline G.; Cust, Anne E.; Menzies, Scott W.; Mann, Graham J.; Morton, Rachael L. (January 2017). "Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma". Journal of Clinical Oncology. 35 (1): 63–71. doi:10.1200/JCO.2016.68.4308. hdl: 2123/30021 . ISSN   0732-183X. PMID   28034073.
  19. ↑ Greenaway, Christina; Pareek, Manish; Abou Chakra, Claire-Nour; Walji, Moneeza; Makarenko, Iuliia; Alabdulkarim, Balqis; Hogan, Catherine; McConnell, Ted; Scarfo, Brittany; Christensen, Robin; Tran, Anh; Rowbotham, Nick; van der Werf, Marieke J.; Noori, Teymur; Pottie, Kevin (April 2018). "The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review". Euro Surveillance. 23 (14): 17–00543. doi:10.2807/1560-7917.ES.2018.23.14.17-00543. ISSN   1560-7917. PMC   5894253 . PMID   29637889.
  20. ↑ Morton, Rachael L.; Schlackow, Iryna; Gray, Alastair; Emberson, Jonathan; Herrington, William; Staplin, Natalie; Reith, Christina; Howard, Kirsten; Landray, Martin J.; Cass, Alan; Baigent, Colin; Mihaylova, Borislava; Collins, R.; Baigent, C.; Landray, M. J. (2018-05-01). "Impact of CKD on Household Income". Kidney International Reports. 3 (3): 610–618. doi:10.1016/j.ekir.2017.12.008. ISSN   2468-0249. PMC   5976816 . PMID   29854968.
  21. ↑ McAlister, Scott; Morton, Rachael L.; Barratt, Alexandra (2022-12-01). "Incorporating carbon into health care: adding carbon emissions to health technology assessments". The Lancet Planetary Health. 6 (12): e993 –e999. doi:10.1016/S2542-5196(22)00258-3. hdl: 2123/30261 . ISSN   2542-5196. PMID   36495894.
  22. ↑ Greenham, Lavern; Bennett, Paul N.; Dansie, Kathryn; Viecelli, Andrea K.; Jesudason, Shilpanjali; Mister, Rebecca; Smyth, Brendan; Westall, Portia; Herzog, Samuel; Brown, Chris; Handke, William; Palmer, Suetonia C.; Caskey, Fergus J.; Couchoud, Cecile; Simes, John (2022-05-19). "The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis". Trials. 23 (1): 419. doi: 10.1186/s13063-022-06355-0 . ISSN   1745-6215. PMC   9118566 . PMID   35590395.
  23. ↑ chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.mja.com.au/system/files/issues/216_01/mja251355.pdf
  24. ↑ Morton, Rachael L.; Shah, Karan K. (January 2021). "Kidney health in the context of economic development". Nature Reviews Nephrology. 17 (1): 5–6. doi:10.1038/s41581-020-00376-1. ISSN   1759-507X. PMC   7684194 . PMID   33235390.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.